Tarcenib
Generic Name
Erlotinib
Manufacturer
Various (generic manufacturers)
Country
Multiple countries, including Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| tarcenib 100 mg tablet | ৳ 500.00 | ৳ 5,000.00 |
| tarcenib 150 mg tablet | ৳ 600.00 | ৳ 6,000.00 |
Description
Overview of the medicine
Tarcenib (Erlotinib) is an oral anticancer medication used to treat non-small cell lung cancer and pancreatic cancer. It works by blocking a protein called Epidermal Growth Factor Receptor (EGFR) which can help cancer cells grow.
Uses & Indications
Dosage
Adults
Non-small cell lung cancer: 150 mg once daily. Pancreatic cancer: 100 mg once daily in combination with gemcitabine.
Elderly
No specific dose adjustment is needed for elderly patients, but careful monitoring for adverse effects is recommended.
Renal_impairment
No dose adjustment is needed for mild to moderate renal impairment. Data limited for severe renal impairment.
How to Take
Take orally at least one hour before or two hours after food. Swallow whole with water.
Mechanism of Action
Erlotinib reversibly inhibits the intracellular phosphorylation of tyrosine kinases associated with the epidermal growth factor receptor (EGFR). It blocks downstream signaling pathways involved in cell proliferation, survival, adhesion, migration, and angiogenesis.
Pharmacokinetics
Onset
Peak plasma concentration typically within 4 hours.
Excretion
Primarily excreted in feces (80%), with a smaller portion excreted in urine (9%).
Half life
Approximately 36 hours.
Absorption
Approximately 60% orally absorbed. Peak plasma concentrations are reached about 4 hours after oral administration. Food increases AUC by ~2-fold.
Metabolism
Primarily hepatic via cytochrome P450 enzymes, mainly CYP3A4, and to a lesser extent CYP1A2. Extensive metabolism to multiple metabolites.
Side Effects
Contraindications
- Severe hypersensitivity to Erlotinib or any components of the formulation.
Drug Interactions
Warfarin
Increased INR and bleeding risk.
CYP3A4 inducers (e.g., rifampicin, phenytoin)
May decrease erlotinib levels, potentially requiring dose increase.
Proton pump inhibitors (PPIs) and H2 antagonists
Reduce erlotinib absorption, avoid co-administration if possible.
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
May increase erlotinib levels, potentially requiring dose reduction.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Overdose experience is limited. Increased frequency and severity of adverse events (e.g., rash, diarrhea) may occur. Management is supportive, and treatment should be discontinued.
Pregnancy & Lactation
Pregnancy Category D. May cause fetal harm. Avoid use during pregnancy. Advise women of childbearing potential to use effective contraception. It is unknown if erlotinib is excreted in human milk; breastfeeding is not recommended.
Side Effects
Contraindications
- Severe hypersensitivity to Erlotinib or any components of the formulation.
Drug Interactions
Warfarin
Increased INR and bleeding risk.
CYP3A4 inducers (e.g., rifampicin, phenytoin)
May decrease erlotinib levels, potentially requiring dose increase.
Proton pump inhibitors (PPIs) and H2 antagonists
Reduce erlotinib absorption, avoid co-administration if possible.
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
May increase erlotinib levels, potentially requiring dose reduction.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Overdose experience is limited. Increased frequency and severity of adverse events (e.g., rash, diarrhea) may occur. Management is supportive, and treatment should be discontinued.
Pregnancy & Lactation
Pregnancy Category D. May cause fetal harm. Avoid use during pregnancy. Advise women of childbearing potential to use effective contraception. It is unknown if erlotinib is excreted in human milk; breastfeeding is not recommended.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from manufacturing date, check packaging for exact date.
Availability
Available in pharmacies and hospitals
Approval Status
Approved (for Erlotinib)
Patent Status
Generics available, original patent expired
Clinical Trials
Erlotinib's efficacy and safety have been established through numerous clinical trials, including the BR.21, SATURN, EURTAC, and IPASS studies for NSCLC, and the PA.3 study for pancreatic cancer.
Lab Monitoring
- Liver function tests (LFTs) at baseline and periodically during treatment.
- Renal function tests if impaired.
- Electrolyte monitoring if severe diarrhea occurs.
Doctor Notes
- Confirm EGFR mutation status in NSCLC patients before initiating therapy.
- Monitor for signs of ILD (new or worsening cough, dyspnea, fever) and discontinue if suspected.
- Manage diarrhea and rash proactively to maintain patient compliance.
Patient Guidelines
- Take on an empty stomach to maximize absorption.
- Report severe or persistent diarrhea, rash, or any new or worsening breathing problems immediately.
- Avoid self-medication for side effects without consulting your doctor.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once.
Driving Precautions
Tarcenib may cause fatigue or blurred vision. Patients should be cautious when driving or operating machinery until they know how the medication affects them.
Lifestyle Advice
- Stay well-hydrated, especially if experiencing diarrhea.
- Use sunscreen and protective clothing as skin rash and sensitivity to sun can occur.
- Maintain good skin hygiene.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Tarcenib Brand
Other medicines available under the same brand name
